PMV Pharmaceuticals, Inc. financial data

Symbol
PMVP on Nasdaq
Location
400 Alexander Park Drive, Suite 301, Princeton, NJ
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.28K % -19.9%
Debt-to-equity 8.5 % -27.4%
Return On Equity -55.3 % -129%
Return On Assets -51 % -135%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 53.2M shares +2.83%
Common Stock, Shares, Outstanding 53M shares +2.4%
Entity Public Float 81.7M USD -61%
Weighted Average Number of Shares Outstanding, Basic 53M shares +2.75%
Weighted Average Number of Shares Outstanding, Diluted 53M shares +2.75%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 67.8M USD +16.6%
General and Administrative Expense 24.3M USD +15.6%
Operating Income (Loss) -92.1M USD -16.4%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -84.9M USD -25.7%
Income Tax Expense (Benefit) -6K USD -108%
Net Income (Loss) Attributable to Parent -82.7M USD -60.7%
Earnings Per Share, Basic -1 USD/shares -61.6%
Earnings Per Share, Diluted -1 USD/shares -61.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 36.3M USD -25.6%
Marketable Securities, Current 92.9M USD -30.7%
Cash, Cash Equivalents, and Short-term Investments 129M USD -34.7%
Assets, Current 132M USD -30.2%
Property, Plant and Equipment, Net 255K USD -97.5%
Operating Lease, Right-of-Use Asset 891K USD -89.4%
Other Assets, Noncurrent 249K USD +2.89%
Assets 134M USD -40.1%
Accounts Payable, Current 3.4M USD +64.8%
Accrued Liabilities, Current 8.52M USD -17%
Liabilities, Current 12.3M USD -9.28%
Operating Lease, Liability, Noncurrent 541K USD -95.5%
Liabilities 12.8M USD -49.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax 91K USD -77.8%
Retained Earnings (Accumulated Deficit) -428M USD -23.9%
Stockholders' Equity Attributable to Parent 121M USD -38.9%
Liabilities and Equity 134M USD -40.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -18.3M USD -12.9%
Net Cash Provided by (Used in) Financing Activities 10K USD
Net Cash Provided by (Used in) Investing Activities 28.7M USD +9.74%
Common Stock, Shares Authorized 1B shares 0%
Common Stock, Shares, Issued 53M shares +2.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 10.5M USD +5.2%
Deferred Tax Assets, Valuation Allowance 96.6M USD +3.02%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0 pure 0%
Deferred Tax Assets, Gross 97M USD +0.64%
Operating Lease, Liability 931K USD -93%
Depreciation 140K USD -90.4%
Payments to Acquire Property, Plant, and Equipment 4K USD -99.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -83M USD -63.8%
Property, Plant and Equipment, Gross 1.55M USD -89.1%
Operating Lease, Liability, Current 390K USD -68.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.14 pure +132%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 186K USD -94.2%
Deferred Tax Assets, Operating Loss Carryforwards 49.7M USD -12.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 3.26M USD +2.71%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 369K USD -85.7%
Share-based Payment Arrangement, Expense 5.83M USD -44.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%